Product Manager: Selina Zhang; Email: selina@coreychem.com
| Product Name | Iobitridol |
| Synonyms |
N1,N3-Bis(2,3-dihydroxypropyl)-5-[[3-hydroxy-2-(hydroxyMethyl)-1-oxopropyl]aMino]-2,4,6-triiodo-N1,N3-diMethyl-1,3-benzenedicarboxaMide;Optiject;Xenetix;N,N’-Bis(2,3-dihydroxypropyl)-5-((5-hydroxy-2-(hydroxymethyl)-1-oxopropyl)amino)-2,4Chemicalbook,6-triiodo-N,N’-dimethyl-1,3-benzenedicarboxamide;1,3-Benzenedicarboxamide,N1,N3-bis(2,3-dihydroxypropyl)-5-[[3-hydroxy-2-(hydroxymethyl)-1-oxopropyl]amino]-2,4,6-triiodo-N1,N3-dimethyl-;IobitridolUSP/EP/BP;IodixanolImpurity20;IOBITRIDOL |
| CAS NO | 136949-58-1 |
| Purity | 98% |
| Appearance |
Off-white to white powder |
| MF | C20H28I3N3O9 |
| MW | 835.16 |
| Contact | selina@coreychem.com |
Iobitridol (CAS: 136949-58-1) is a non-ionic, low-osmolar iodinated contrast agent designed for diagnostic radiology. With its tri-iodinated benzene core and hydrophilic side chains, it provides high radiopacity and favorable safety performance in clinical imaging. Its primary applications are outlined below:
1. Diagnostic Imaging Applications
X-ray and Computed Tomography (CT) Enhancement
Iobitridol is widely used as an intravascular contrast medium to enhance the visualization of blood vessels, organs, and soft tissues during X-ray and CT examinations. The high iodine content enables strong attenuation of X-rays, significantly improving image clarity and diagnostic accuracy.
Angiography
It is applied in cerebral, peripheral, and coronary angiography to provide detailed imaging of vascular structures. Its low osmolality helps reduce vascular discomfort and adverse reactions during injection.
Urography
Iobitridol is used in intravenous urography and CT urography to enhance imaging of the kidneys, ureters, and bladder, assisting in the diagnosis of structural abnormalities, obstructions, or tumors.
Arthrography and Other Cavity Examinations
It may be administered intra-articularly or into body cavities to visualize joint spaces and other anatomical structures under fluoroscopy.
2. Clinical Safety & Pharmacological Profile
Non-Ionic, Low-Osmolar Characteristics
As a non-ionic contrast agent, Iobitridol demonstrates improved patient tolerance compared with high-osmolar ionic contrast agents. Lower osmolality contributes to reduced risk of pain, endothelial irritation, and fluid imbalance.
Rapid Renal Elimination
The compound is primarily excreted unchanged via the kidneys, with minimal metabolism, supporting predictable pharmacokinetics and short systemic retention time.
3. Research and Development Use
Radiographic Formulation Studies
Iobitridol serves as a model compound in the development of next-generation iodinated contrast agents, focusing on improving biocompatibility, reducing nephrotoxicity, and optimizing imaging performance.
Comparative Clinical Studies
It is utilized in clinical research evaluating safety profiles, contrast enhancement efficiency, and patient tolerance versus other iodinated contrast media.
4. Points to Note
-
Administration: Intended for professional medical use under controlled clinical conditions.
-
Storage: Should be stored according to pharmacopeial guidelines to maintain stability and sterility.
-
Safety Considerations: Renal function assessment is recommended prior to administration, especially in high-risk patients.
Summary
The core value of Iobitridol lies in its optimized balance between radiographic efficacy and patient safety. As a non-ionic, low-osmolar iodinated contrast medium, it plays a critical role in modern diagnostic imaging, particularly in CT and angiographic procedures, while also supporting ongoing pharmaceutical research in contrast media development.
